Our Pricing

Your Mounjaro NHS Criteria Questions Answered

Understanding Mounjaro NHS criteria UK requirements is essential before requesting a prescription from your GP. At Cured Pharmacy, our UK-registered clinical team answers the most common eligibility questions and provides private prescription options when NHS criteria aren't met, with transparent pricing from £135.00 and free online consultations completed in under three minutes.

What Are the Current Mounjaro NHS Criteria UK Requirements?

The NHS prescribes Mounjaro (tirzepatide) under strict NICE guidance that prioritises patients with the highest clinical need [1]. To qualify for NHS-funded Mounjaro, you typically need a BMI of 35 kg/m² or above with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea. Patients with a BMI of 30-34.9 kg/m² may qualify if they have type 2 diabetes and specific HbA1c levels indicating inadequate glycaemic control [1].

NICE guidelines also require evidence of previous weight management attempts, including participation in a structured lifestyle programme for at least three months [2]. Your GP must document that conventional approaches have not achieved adequate weight loss before initiating Mounjaro on the NHS. Additionally, local integrated care boards (ICBs) may impose further restrictions based on regional formularies and budget constraints, meaning availability varies significantly across England, Scotland, Wales, and Northern Ireland.

It's important to understand that even if you meet the clinical criteria, NHS supply of Mounjaro remains limited due to national shortages and prioritisation protocols. Many GP surgeries maintain waiting lists or have temporarily suspended new initiations whilst existing patients are prioritised. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) regularly advises patients who meet clinical suitability but cannot access NHS prescriptions within a reasonable timeframe.

BMI Thresholds and Weight-Related Comorbidities Explained

Body Mass Index (BMI) forms the foundation of Mounjaro NHS criteria UK assessments, but it's not the sole determining factor. A BMI of 35 kg/m² or higher automatically qualifies you for consideration if you also have at least one obesity-related comorbidity. These comorbidities include type 2 diabetes mellitus, hypertension requiring pharmacological treatment, dyslipidaemia, cardiovascular disease, non-alcoholic fatty liver disease (NAFLD), polycystic ovary syndrome (PCOS), or obstructive sleep apnoea confirmed by sleep studies [2].

For patients with type 2 diabetes, the threshold drops to a BMI of 30 kg/m². However, your HbA1c must demonstrate inadequate glycaemic control despite optimised oral antidiabetic medications or existing GLP-1 therapy. NICE specifies that tirzepatide should be considered when current treatments haven't achieved target HbA1c levels, typically defined as sustained readings above 58 mmol/mol (7.5%) [1][2].

Ethnic-specific BMI adjustments also apply under NHS criteria. Patients of South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean family origin may qualify at lower BMI thresholds—typically 32.5 kg/m² instead of 35 kg/m²—due to increased metabolic risk at lower body weights. Your GP should apply these adjusted thresholds during eligibility assessments, though awareness varies between practices.

When Private Prescriptions Become Necessary

If your BMI falls below NHS thresholds but you're clinically suitable for weight loss medication, private prescription services offer a legitimate alternative. At Cured Pharmacy, our UK-registered prescribers assess patients with a BMI of 27 kg/m² or above who have at least one weight-related health concern, or a BMI of 30 kg/m² or above regardless of comorbidities. This broader eligibility framework aligns with MHRA licensing conditions and provides access when NHS criteria create barriers to appropriate treatment.

How Long Must You Try Other Treatments Before Mounjaro?

NHS protocols require documented evidence of previous weight management attempts before Mounjaro can be prescribed. NICE guidance mandates participation in a specialist weight management service or structured lifestyle programme for a minimum of three months, with regular monitoring and professional support [2]. These programmes must include dietary modification, increased physical activity, and behavioural change strategies delivered by trained healthcare professionals.

Your GP will review whether you've achieved at least 5% body weight reduction through conventional methods during this period. If lifestyle interventions alone haven't produced adequate results, pharmacological options like orlistat may be trialled first, particularly if your BMI is between 30-34.9 kg/m². Only after demonstrating insufficient response to these first-line approaches does Mounjaro become an NHS consideration under current commissioning frameworks.

Private prescription pathways don't always require the same stepped-care approach, though responsible prescribers still assess your weight management history. At Cured Pharmacy, our clinical team evaluates previous attempts and current health status to determine the most appropriate treatment. This may include orlistat-based options starting from £135.00 or injectable GLP-1 treatments depending on your individual circumstances and clinical suitability.

Mounjaro vs Other Weight Loss Treatments: Clinical Effectiveness

Tirzepatide's dual GIP/GLP-1 receptor agonist mechanism distinguishes it from single-pathway alternatives like semaglutide (Wegovy, Saxenda) and orlistat. In the SURMOUNT-1 trial, participants without diabetes achieved average body weight reductions of 15.0% with the 5 mg dose, 19.5% with 10 mg, and 20.9% with 15 mg over 72 weeks—significantly higher than comparator treatments [3]. These results positioned tirzepatide as the most effective pharmacological obesity treatment currently licensed in the UK.

Semaglutide, available as Wegovy for weight management, demonstrated average weight loss of 14.9% over 68 weeks in the STEP 1 trial [4]. Whilst this represents substantial clinical benefit, head-to-head comparisons suggest tirzepatide produces greater reductions in both body weight and cardiometabolic markers. Saxenda (liraglutide), a daily injection, typically achieves 5-10% weight loss, whilst orlistat—a lipase inhibitor—produces more modest reductions of 3-5% when combined with dietary restriction [2][4].

Treatment choice depends on multiple factors beyond efficacy data, including injection frequency preferences, side effect profiles, cost considerations, and individual response patterns. Our UK prescribers assess your medical history, previous treatment experiences, and personal circumstances to recommend the most suitable option. All GLP-1 treatments require ongoing lifestyle modifications and regular clinical monitoring to optimise outcomes and ensure safety.

Understanding Injection Frequency and Dosing Schedules

Mounjaro requires once-weekly subcutaneous injection, starting at 2.5 mg and titrating upward every four weeks based on tolerability and response. Maximum licensed dose is 15 mg weekly for weight management. Wegovy follows a similar weekly schedule, whilst Saxenda requires daily injections, which some patients find less convenient. Orlistat capsules are taken three times daily with meals, offering a non-injectable alternative for those unsuitable for or unwilling to use GLP-1 treatments.

What Happens If You Don't Meet Mounjaro NHS Criteria UK Standards?

Failing to meet NHS eligibility criteria doesn't mean you're unsuitable for Mounjaro—it simply indicates you don't qualify for publicly funded treatment under current commissioning frameworks. Private prescription services operate under broader MHRA licensing conditions, which permit tirzepatide use in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity [1]. This creates legitimate access for clinically appropriate patients who fall outside NHS thresholds.

At Cured Pharmacy, our online consultation process takes under three minutes and connects you with UK-registered prescribers who assess your individual suitability. We provide transparent upfront pricing with Mounjaro available from £135.00, eliminating the uncertainty often associated with private weight management services. All consultations are free, and you'll know your treatment cost before any prescriber assessment, ensuring complete transparency throughout the process.

If Mounjaro isn't clinically appropriate for your circumstances, our prescribers may recommend alternative treatments including Wegovy, Saxenda, or orlistat-based options depending on your BMI, medical history, and treatment goals. Every prescription medication we dispense is UK-licensed and sourced through regulated supply chains, with discreet packaging and delivery arranged through our GPhC-registered pharmacy (registration number 9012511).

Private Prescription Costs and What's Included

Private Mounjaro prescriptions at Cured Pharmacy start from £135.00 per month, with final costs determined by your prescribed dose strength. This includes the medication, UK prescriber consultation, and discreet home delivery. Unlike some services, we display prices before consultation, ensuring you can make informed decisions without unexpected charges. Our lowest price guarantee means you're accessing competitive UK pricing with the convenience of a fully regulated online pharmacy service.

Monitoring Requirements and Ongoing Support With Mounjaro

Whether prescribed via NHS or private routes, Mounjaro requires regular clinical monitoring to ensure safety and effectiveness. NICE recommends reviewing treatment response every three months during the first year, assessing weight loss progress, tolerability, adherence to lifestyle modifications, and any emerging side effects [2]. Prescribers should discontinue treatment if patients haven't achieved at least 5% body weight reduction after six months at the maximum tolerated dose, unless significant improvements in cardiometabolic markers justify continuation.

Common side effects include gastrointestinal symptoms such as nausea, diarrhoea, vomiting, constipation, and abdominal discomfort, particularly during dose escalation phases [3]. These typically diminish over time as your body adjusts to treatment. More serious but rare adverse effects include pancreatitis, gallbladder disease, and hypoglycaemia in patients taking concomitant diabetes medications. Your prescriber should provide clear guidance on recognising warning signs and when to seek urgent medical attention.

At Cured Pharmacy, ongoing prescriptions require periodic reassessment by our clinical team to evaluate continued suitability and treatment response. We maintain detailed records of your progress and coordinate with your NHS GP when appropriate to ensure continuity of care. Our superintendent pharmacist Tarun Kumar oversees all clinical protocols, ensuring every patient receives pharmacy care that meets GPhC standards and prioritises safety alongside treatment effectiveness.

Scientific References

1. National Institute for Health and Care Excellence. (2023). Tirzepatide for treating type 2 diabetes [TA924]. NICE. https://www.nice.org.uk/guidance/ta924
2. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management [CG189]. NICE. https://www.nice.org.uk/guidance/cg189
3. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
4. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Mounjaro is a prescription-only medicine and suitability is determined on an individual basis following comprehensive medical review.